{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-179235","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2022-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.347163+00:00","generated_at":"2026-06-24T23:39:15.157172+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Viridian Therapeutics appoints Carrie Melvin as COO, effective June 21, 2022","bullets":["Carrie Melvin named COO; previously SVP Clinical Development at X4 Pharmaceuticals (Nasdaq: XFOR).","Base salary $425K, sign-on bonus $60K, target bonus 40% of base salary.","Receives inducement option for 210,000 shares vesting over 4 years (25% at 1-year cliff).","Melvin brings 20+ years experience from GSK, TESARO, and Kura Oncology.","Position is newly created; company advancing late-stage clinical development for TED programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-179235","json":"https://secwatch.observer/filing/0001193125-22-179235.json","markdown":"https://secwatch.observer/filing/0001193125-22-179235.md","text":"https://secwatch.observer/filing/0001193125-22-179235.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312522179235/0001193125-22-179235-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312522179235/d318381d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T23:39:15.157172+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"addde376db","claim":"Carrie Melvin was appointed as Chief Operating Officer at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"On June 21, 2022, the board of directors of Viridian Therapeutics, Inc. (the “Company”) appointed Carrie Melvin as Chief Operating Officer of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312522179235/0001193125-22-179235-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}